Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism



Page Path
HOME > Search
1 "Fibric acids"
Article type
Publication year
Funded articles
Review Article
Diabetes, Obesity and Metabolism
Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
Joon Ho Moon, Kyuho Kim, Sung Hee Choi
Endocrinol Metab. 2022;37(4):575-586.   Published online August 29, 2022
  • 9,131 View
  • 464 Download
  • 14 Web of Science
  • 17 Crossref
AbstractAbstract PDFPubReader   ePub   
High levels of triglycerides (TG) and triglyceride-rich lipoproteins (TGRLs) confer a residual risk of cardiovascular disease after optimal low-density lipoprotein cholesterol (LDL-C)–lowering therapy. Consensus has been made that LDL-C is a non-arguable primary target for lipid lowering treatment, but the optimization of TGRL for reducing the remnant risk of cardiovascular diseases is urged. Omega-3 fatty acids and fibrates are used to reduce TG levels, but many patients still have high TG and TGRL levels combined with low high-density lipoprotein concentration that need to be ideally treated. Lipoprotein lipase (LPL) is a key regulator for TGs that hydrolyzes TGs to glycerol and free fatty acids in lipoprotein particles for lipid storage and consumption in peripheral organs. A deeper understanding of human genetics has enabled the identification of proteins regulating the LPL activity, which include the apolipoproteins and angiopoietin-like families. Novel therapeutic approach such as antisense oligonucleotides and monoclonal antibodies that regulate TGs have been developed in recent decades. In this article, we focus on the biology of LPL and its modulators and review recent clinical application, including genetic studies and clinical trials of novel therapeutics. Optimization of LPL activity to lower TG levels could eventually reduce incident atherosclerotic cardiovascular disease in conjunction with successful LDL-C reduction.


Citations to this article as recorded by  
  • The chylomicron saga: time to focus on postprandial metabolism
    Alejandro Gugliucci
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Sanghuangporus vaninii extract ameliorates hyperlipidemia in rats by mechanisms identified with transcriptome analysis
    Ning Gao, Yuanzhen Liu, Guangjie Liu, Bo Liu, Yupeng Cheng
    Food Science & Nutrition.2024; 12(5): 3360.     CrossRef
  • Targeting host-specific metabolic pathways—opportunities and challenges for anti-infective therapy
    Monika I. Konaklieva, Balbina J. Plotkin
    Frontiers in Molecular Biosciences.2024;[Epub]     CrossRef
  • Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024
    Harold Edward Bays, Carol Kirkpatrick, Kevin C. Maki, Peter P. Toth, Ryan T. Morgan, Justin Tondt, Sandra Michelle Christensen, Dave Dixon, Terry A. Jacobson
    Obesity Pillars.2024; 10: 100108.     CrossRef
  • Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review
    Chaicharn Deerochanawong, Sin Gon Kim, Yu-Cheng Chang
    Diabetes & Metabolism Journal.2024; 48(2): 184.     CrossRef
  • Xanthohumol, a prenylated chalcone, regulates lipid metabolism by modulating the LXRα/RXR-ANGPTL3-LPL axis in hepatic cell lines and high-fat diet-fed zebrafish models
    Wan-Yun Gao, Pei-Yi Chen, Hao-Jen Hsu, Je-Wen Liou, Chia-Ling Wu, Ming-Jiuan Wu, Jui-Hung Yen
    Biomedicine & Pharmacotherapy.2024; 174: 116598.     CrossRef
  • Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024
    Harold Edward Bays, Carol Kirkpatrick, Kevin C. Maki, Peter P. Toth, Ryan T. Morgan, Justin Tondt, Sandra Michelle Christensen, Dave Dixon, Terry A. Jacobson
    Journal of Clinical Lipidology.2024;[Epub]     CrossRef
  • Factors associated with treatment responses to pioglitazone in patients with steatotic liver disease: A 3‐year prospective cohort study
    Ming‐Ling Chang, Jennifer Tai, Jur‐Shan Cheng, Wei‐Ting Chen, Sien‐Sing Yang, Cheng‐Hsun Chiu, Rong‐Nan Chien
    Diabetes, Obesity and Metabolism.2024; 26(7): 2969.     CrossRef
  • Efficacy and safety of omega‐3‐acid ethyl acetate 90 capsules in severe hypertriglyceridemia: A randomized, controlled, multicenter study
    Wang Zhao, Yangang Wang, Jin Li, Tao Chen, Delu Yin, Hailong Dai, Zhuhua Yao, Shuiping Zhao
    Lipids.2024;[Epub]     CrossRef
  • High producer variant of lipoprotein lipase may protect from hepatocellular carcinoma in alcohol-associated cirrhosis
    Franziska Schmalz, Janett Fischer, Hamish Innes, Stephan Buch, Christine Möller, Madlen Matz-Soja, Witigo von Schönfels, Benjamin Krämer, Bettina Langhans, Alexandra Klüners, Michael Soyka, Felix Stickel, Jacob Nattermann, Christian P. Strassburg, Thomas
    JHEP Reports.2023; 5(4): 100684.     CrossRef
  • Measurement of Serum Low Density Lipoprotein Cholesterol and Triglyceride-Rich Remnant Cholesterol as Independent Predictors of Atherosclerotic Cardiovascular Disease: Possibilities and Limitations
    Dieter Lütjohann, Hans-Ulrich Klör, Frans Stellaard
    Nutrients.2023; 15(9): 2202.     CrossRef
  • Influence of antipsychotic medications on hyperlipidemia risk in patients with schizophrenia: evidence from a population-based cohort study and in vitro hepatic lipid homeostasis gene expression
    Tien-Yuan Wu, Ni Tien, Cheng-Li Lin, Yu-Cun Cheah, Chung Y. Hsu, Fuu-Jen Tsai, Yi-Jen Fang, Yun-Ping Lim
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux
    Alejandro Gugliucci
    Journal of Clinical Medicine.2023; 12(13): 4399.     CrossRef
  • Sugar and Dyslipidemia: A Double-Hit, Perfect Storm
    Alejandro Gugliucci
    Journal of Clinical Medicine.2023; 12(17): 5660.     CrossRef
  • Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview
    Sang Heon Suh, Soo Wan Kim
    Diabetes & Metabolism Journal.2023; 47(5): 612.     CrossRef
  • Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease
    Elena Valeria Fuior, Evangelia Zvintzou, Theodosios Filippatos, Katerina Giannatou, Victoria Mparnia, Maya Simionescu, Anca Violeta Gafencu, Kyriakos E. Kypreos
    Biomedicines.2023; 11(10): 2696.     CrossRef
  • Developing a model to predict the early risk of hypertriglyceridemia based on inhibiting lipoprotein lipase (LPL): a translational study
    Julia Hernandez-Baixauli, Gertruda Chomiciute, Juan María Alcaide-Hidalgo, Anna Crescenti, Laura Baselga-Escudero, Hector Palacios-Jordan, Elisabet Foguet-Romero, Anna Pedret, Rosa M. Valls, Rosa Solà, Miquel Mulero, Josep M. Del Bas
    Scientific Reports.2023;[Epub]     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism